Urothelial carcinoma (CU) of urinary tract, also known as cell carcinoma transitional of the urinary tract, represents around 85-95% of all the cancers of the urinary tract. The term urothelial refers to the epithelium that covers the urinary tract (uroteli or epithelium of transition), which include the kidney pelvis, ureters, the bladder and two thirds of the urethra. More than 90% of the tumors of the urothelial tract originate in the urinary bladder, while 8% correspond to tumors originating in the renal pelvis and the remaining 2% in urinary and urethra. The incidence of bladder cancer is three times higher in men than in women, with a median age at the diagnosis of 65 years. It is the fifth type of cancer most frequently diagnosed in Spain, only after colon, prostate, lung and breast (fourth in men)
Urothelial carcinoma; Atezolizumab; Adult patients
Programa d'Harmonització Farmacoterapèutica. Atezolizumab per al tractament del carcinoma urotelial localment avançat o metastàtic. Barcelona: Servei Català de la Salut; 2018.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/4271
This item appears in following collections
The following license files are associated with this item: